Although the widely prescribed Lyrica painkiller was studied for more than 30 other uses, a new analysis finds much of the subsequent testing appears to have been merely exploratory, creating perceptions that the drug could combat other maladies and encouraging off-label use.

Specifically, a systematic review of 238 clinical trials for unapproved uses found that 67 percent of the studies that examined 33 additional indications generated uncertainty about the effectiveness of the drug, according to the analysis published in JAMA Internal Medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy